Chamomile Extract

Natural cannabinoid from hemp

Indena SpA offers a wide range of pharmaceutical products which includes cascara sagrada extract. Botanical origin: rhamnus purshiana dc. bark. Biological activity: laxative. Contact us for more information.

Indena SpA offers a wide range of pharmaceutical products which includes centella asiatica selected triterpenes. Botanical origin: centella asiatica (l.) urban leaf. Biological activity: cicatrizing-trophodermic. Contact us for more information.

Colchicine micronized. Botanical origin: gloriosa superba l. seed. Biological activity: antigout.

We have a unique expertise in developing and manufacturing HPAPIs. The company is equipped with kilolabs (for clinical and small commercial batches) and large industrial suite for HPAPIs with an OEL>20 ng/m3.

Have a look at the interview with Indena and their BD & Licensing Director, Stefano Togni. In the interview she talks about, among other things, their facilities around the world and what updates they have to offer.

This session was originally broadcast as part of the CPHI Worldwide 2021 digital content programme. Growth in the highly potent active pharmaceutical ingredients segment means there is strong demand for specialist outsourcing solutions for their manufacture. CDMOs don’t just need to have the right equipment and facilities; they also need to convince sponsors that they possess the in-depth knowledge of safety practices and containment technology. In this CPHI Worldwide podcast with Carlo Aloni, Production and Process Technology Director at Indena, we looked at the various challenges of HPAPI production, the latest innovative technologies and what Indena is currently working towards in this highly promising growth sector.

This podcast was originally broadcast as part of the CPHI Worldwide 2021 digital content programme. When a pharmaceutical sponsor company decides it wishes to outsource vital functions such as manufacturing, drug development, and formulation, they are looking for several key qualities in a service provider. CDMOs need to provide flexibility, collaboration and innovation, as well as the ability to continuously evolve their offering. In this CPHI Worldwide podcast with Stefano Togni, Business Development Director at Indena, we explore how CDMOs are adapting to changing market conditions amid these challenging times.

This session was originally broadcast as part of the CPHI Worldwide 2021 digital content programme. 2021 has been the second year of a very difficult and challenging global pandemic, to which the pharmaceutical industry has had to respond with resilience and flexibility. Coincidentally, it is also the centenary year of API contract developer and supplier, Indena. In this CPHI Worldwide podcast with Francesca de Rensis, Marketing Director at Indena, we take a look back at the proud 100 years of history that have shaped the company into the international business it is today as well as examining the main supply chain challenges facing that have defined the year 2021.

Indena is relentlessly working to generate a sustainable impact on its stakeholders, cultivating with care its own precious circle: Nature, Technology, and People. In terms of actual projects and actions, Indena's commitment in sustainability includes responsible supply chain management, a circular economy in product design, and very smart use of energy in its plants. As for energy use, which is linked to climate change, one of the most urgent global sustainability challenges, Indena has been working for years to reduce consumption, save energy, and achieve high levels of energy self-production. All the actions taken for sustainability allow Indena to be fully reliable in terms of business continuity and thus be a solid partner for all its clients.